The Latest Cardiac and Vascular News
SANTA CRUZ, Calif., May 9, 2023 /PRNewswire/ — Emboline, Inc., a privately held medical technology company focused on reducing stroke during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced the first patient has been treated in the Protect the Head to Head investigational device exemption (IDE) clinical trial […]
Financing led by Matrix Capital Management with significant investment from an undisclosed strategic investor — Eric Xiao of Matrix Capital Management to join the Emboline Board of Directors SANTA CRUZ, Calif., May 25, 2021 /PRNewswire/ — Emboline, Inc., a privately held medical device company focused on reducing stroke and other damage caused by embolic […]
In the SafePass 2 clinical study, the Emboliner™ demonstrated excellent safety and technical performance, and captured five times more debris than commercially-available devices SANTA CRUZ, Calif., Jan. 5, 2021 /PRNewswire/ — Emboline, Inc., a privately held medical technology company focused on reducing stroke during transcatheter heart procedures, today announced it completed raising over $10 […]
SANTA CRUZ, Calif.–(BUSINESS WIRE)–Emboline™, Inc., developer of embolic protection technology for brain and body during transcatheter aortic valve replacement (TAVR), today announced the closing of a $5 million bridge round of financing from a number of existing and new investors. This financing is ahead of an expected Series C financing […]
Early Results from First 24 Patients Show Excellent Safety Profile and Technical Performance, with Significant Debris Capture and Removal in All Patients SANTA CRUZ, Calif.–(BUSINESS WIRE)–Emboline™, Inc., developer of total embolic protection technology for transcatheter aortic valve replacement (TAVR), today announced completion of enrollment in its SafePass™ 2 clinical study […]
SANTA CRUZ, Calif., June 5, 2018 /PRNewswire/ — Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today the successful completion of its initial series of human clinical cases using the EmbolinerTM Embolic Protection Catheter. The initial procedures were performed at […]
SANTA CRUZ, Calif., April 19, 2018 /PRNewswire/ — Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today that it has completed a Series B funding round totaling over $10 million. The funding includes $3 million in new […]
